Sumitra Thongprasert
Impact in
- Pulmonary and Respiratory Medicine top 0.02%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Oncology top 0.1%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Papers in
-
- Lung Cancer Treatments and Mutations 47
- Lung Cancer Diagnosis and Treatment 9
- Oncology 29
- Colorectal Cancer Treatments and Studies 7
- Lung Cancer Research Studies 7
- Cancer Treatment and Pharmacology 4
- Co-authors
- Yi‐Long Wu (13 shared papers)Tony Mok (15 shared papers)Masahiro Fukuoka (6 shared papers)Patrapim Sunpaweravong (4 shared papers)Nagahiro Saijo (6 shared papers)Emma Duffield (4 shared papers)Alison Armour (3 shared papers)Haiyi Jiang (2 shared papers)
In The Last Decade
Sumitra Thongprasert
88 papers receiving 18.4k citations
Sumitra Thongprasert's Hit Papers
Peers
Comparison fields: 5 of 119
- Pulmonary and Respiratory Medicine 12.5k
- Oncology 8.1k
- Cancer Research 2.7k
- Otorhinolaryngology 400
- Hepatology 531
Countries citing papers authored by Sumitra Thongprasert
This map shows the geographic impact of Sumitra Thongprasert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sumitra Thongprasert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sumitra Thongprasert more than expected).
Fields of papers citing papers by Sumitra Thongprasert
This network shows the impact of papers produced by Sumitra Thongprasert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sumitra Thongprasert. The network helps show where Sumitra Thongprasert may publish in the future.
Co-authors
The 25 scholars most cited alongside Sumitra Thongprasert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 92 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Hit paper breakdown → | 2009 | 6539 |
| 2 | Erlotinib in Previously Treated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2005 | 4412 |
| 3 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Hit paper breakdown → | 2005 | 1742 |
| 4 | Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) Hit paper breakdown → | 2011 | 1216 |
| 5 | A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) Hit paper breakdown → | 2014 | 1135 |
| 6 | Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis Hit paper breakdown → | 2013 | 398 |
| 7 | Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy Hit paper breakdown → | 2015 | 375 |
| 8 | Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia Hit paper breakdown → | 2013 | 373 |
| 9 | 2011 | 248 | |
| 10 | 1998 | 237 | |
| 11 | 2016 | 202 | |
| 12 | 2012 | 176 | |
| 13 | 2006 | 149 | |
| 14 | 2015 | 131 | |
| 15 | 2005 | 130 | |
| 16 | 2005 | 127 | |
| 17 | 1999 | 122 | |
| 18 | 2006 | 113 | |
| 19 | 2011 | 110 | |
| 20 | 1998 | 106 |
About Sumitra Thongprasert
Sumitra Thongprasert is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Molecular Biology and Hepatology, having authored 92 papers that have together received 18.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (47 papers), Lung Cancer Diagnosis and Treatment (9 papers), Hepatocellular Carcinoma Treatment and Prognosis (8 papers), Colorectal Cancer Treatments and Studies (7 papers), Lung Cancer Research Studies (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Cancer Genomics and Diagnostics (5 papers) and Cancer Treatment and Pharmacology (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (12.5k citations), Oncology (8.1k citations), Cancer Research (2.7k citations), Otorhinolaryngology (400 citations) and Hepatology (531 citations). Sumitra Thongprasert has collaborated with scholars based in Thailand, China and Taiwan. Frequent co-authors include Yi‐Long Wu, Tony Mok, Masahiro Fukuoka, Patrapim Sunpaweravong, Nagahiro Saijo, Emma Duffield, Alison Armour, Haiyi Jiang, Tudor–Eliade Ciuleanu and José Rodrigues Pereira. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Lung Cancer, Annals of Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.